Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CERE |
---|---|---|
09:32 ET | 10988 | 36.79 |
09:34 ET | 508 | 37.21 |
09:38 ET | 1563 | 37.3675 |
09:39 ET | 200 | 37.18 |
09:41 ET | 4799 | 37.96 |
09:43 ET | 1225 | 38.05 |
09:45 ET | 1912 | 38.12 |
09:48 ET | 402 | 38.22 |
09:50 ET | 2220 | 38.23 |
09:52 ET | 6620 | 38.33 |
09:54 ET | 1800 | 38.39 |
09:56 ET | 1000 | 38.4848 |
09:57 ET | 1708 | 38.335 |
09:59 ET | 850 | 38.5 |
10:01 ET | 11341 | 38.34 |
10:03 ET | 1171 | 38.14 |
10:06 ET | 1500 | 37.815 |
10:08 ET | 300 | 37.59 |
10:10 ET | 600 | 37.43 |
10:14 ET | 1207 | 37.55 |
10:15 ET | 307 | 37.495 |
10:17 ET | 7334 | 37.55 |
10:19 ET | 1134 | 37.68 |
10:21 ET | 3858 | 38 |
10:24 ET | 800 | 37.79 |
10:26 ET | 643 | 37.69 |
10:28 ET | 1100 | 37.9 |
10:30 ET | 1100 | 37.83 |
10:32 ET | 1235 | 37.94 |
10:33 ET | 2400 | 38.55 |
10:35 ET | 300 | 38.705 |
10:37 ET | 3300 | 38.5 |
10:39 ET | 920 | 38.51 |
10:42 ET | 544 | 38.445 |
10:44 ET | 550 | 38.33 |
10:46 ET | 2300 | 38.37 |
10:48 ET | 2692 | 38.26 |
10:50 ET | 1100 | 38.02 |
10:51 ET | 900 | 38.4379 |
10:53 ET | 200 | 38.38 |
10:55 ET | 300 | 38.27 |
10:57 ET | 700 | 38.375 |
11:00 ET | 1100 | 38.39 |
11:02 ET | 1112 | 38.065 |
11:04 ET | 500 | 38.15 |
11:06 ET | 300 | 37.98 |
11:08 ET | 500 | 38.07 |
11:09 ET | 867 | 37.97 |
11:13 ET | 3200 | 38.18 |
11:15 ET | 300 | 38.305 |
11:18 ET | 800 | 38.435 |
11:20 ET | 846 | 38.535 |
11:22 ET | 410 | 38.5 |
11:24 ET | 1400 | 38.315 |
11:27 ET | 500 | 38.345 |
11:29 ET | 1200 | 38.27 |
11:31 ET | 400 | 38.205 |
11:33 ET | 442 | 38.06 |
11:36 ET | 3000 | 38.23 |
11:38 ET | 1469 | 38.45 |
11:40 ET | 200 | 38.36 |
11:42 ET | 800 | 38.24 |
11:44 ET | 39433 | 38.78 |
11:45 ET | 19242 | 38.83 |
11:47 ET | 1827 | 38.725 |
11:49 ET | 1325 | 38.57 |
11:51 ET | 10090 | 38.555 |
11:54 ET | 905 | 38.49 |
11:56 ET | 500 | 38.28 |
11:58 ET | 1487 | 38.36 |
12:00 ET | 1292 | 38.13 |
12:02 ET | 200 | 38.13 |
12:03 ET | 800 | 38.37 |
12:05 ET | 1125 | 38.5 |
12:07 ET | 1266 | 38.515 |
12:09 ET | 1515 | 38.725 |
12:12 ET | 200 | 38.71 |
12:14 ET | 700 | 38.655 |
12:16 ET | 1937 | 38.58 |
12:18 ET | 3457 | 38.61 |
12:20 ET | 300 | 38.61 |
12:21 ET | 1700 | 38.58 |
12:23 ET | 800 | 38.5 |
12:25 ET | 3009 | 38.78 |
12:27 ET | 400 | 38.83 |
12:30 ET | 1300 | 38.705 |
12:32 ET | 100 | 38.62 |
12:34 ET | 200 | 38.69 |
12:36 ET | 300 | 38.705 |
12:38 ET | 5435 | 38.861 |
12:39 ET | 1000 | 38.705 |
12:41 ET | 3926 | 38.6 |
12:43 ET | 1700 | 38.57 |
12:45 ET | 3298 | 38.485 |
12:48 ET | 6846 | 38.535 |
12:50 ET | 11228 | 38.395 |
12:52 ET | 3346 | 38.39 |
12:54 ET | 2388 | 38.42 |
12:56 ET | 2231 | 38.42 |
12:57 ET | 5200 | 38.485 |
12:59 ET | 1488 | 38.435 |
01:01 ET | 900 | 38.515 |
01:03 ET | 6100 | 38.6 |
01:06 ET | 14997 | 38.53 |
01:08 ET | 12243 | 38.595 |
01:10 ET | 1000 | 38.565 |
01:12 ET | 1375 | 38.57 |
01:14 ET | 10080 | 38.565 |
01:15 ET | 3136 | 38.4197 |
01:17 ET | 1319 | 38.46 |
01:19 ET | 400 | 38.48 |
01:21 ET | 3073 | 38.56 |
01:24 ET | 11700 | 38.49 |
01:26 ET | 3140 | 38.555 |
01:28 ET | 1643 | 38.475 |
01:30 ET | 3205 | 38.525 |
01:32 ET | 749 | 38.56 |
01:33 ET | 1600 | 38.5 |
01:35 ET | 1153 | 38.39 |
01:37 ET | 1727 | 38.33 |
01:39 ET | 2487 | 38.2 |
01:42 ET | 100 | 38.235 |
01:44 ET | 2961 | 38.39 |
01:46 ET | 1780 | 38.5 |
01:48 ET | 900 | 38.65 |
01:51 ET | 100 | 38.82 |
01:55 ET | 1198 | 38.76 |
01:57 ET | 300 | 38.76 |
02:00 ET | 500 | 38.76 |
02:02 ET | 100 | 38.76 |
02:04 ET | 5600 | 38.7 |
02:06 ET | 300 | 38.645 |
02:08 ET | 2748 | 38.5 |
02:09 ET | 3139 | 38.705 |
02:11 ET | 400 | 38.7 |
02:13 ET | 6640 | 38.72 |
02:15 ET | 964 | 38.75 |
02:18 ET | 1300 | 38.86 |
02:20 ET | 200 | 38.88 |
02:22 ET | 2300 | 38.745 |
02:24 ET | 3160 | 38.76 |
02:26 ET | 100 | 38.765 |
02:27 ET | 300 | 38.74 |
02:29 ET | 1300 | 38.54 |
02:31 ET | 1100 | 38.5 |
02:33 ET | 1846 | 38.675 |
02:36 ET | 2100 | 38.73 |
02:38 ET | 600 | 38.9 |
02:40 ET | 1006 | 38.935 |
02:42 ET | 3522 | 38.91 |
02:44 ET | 4620 | 38.85 |
02:45 ET | 1745 | 39 |
02:47 ET | 4840 | 39 |
02:49 ET | 400 | 39 |
02:51 ET | 4471 | 39.025 |
02:54 ET | 5664 | 39.05 |
02:56 ET | 3424 | 38.77 |
02:58 ET | 1963 | 38.88 |
03:00 ET | 700 | 39.065 |
03:02 ET | 600 | 39.155 |
03:03 ET | 9305 | 39.3 |
03:05 ET | 3155 | 39.315 |
03:07 ET | 1738 | 39.375 |
03:09 ET | 2632 | 39.38 |
03:12 ET | 3590 | 39.4 |
03:14 ET | 600 | 39.315 |
03:16 ET | 1351 | 39.31 |
03:18 ET | 2726 | 39.375 |
03:20 ET | 3627 | 39.47 |
03:21 ET | 9800 | 39.44 |
03:23 ET | 7848 | 39.45 |
03:25 ET | 2879 | 39.48 |
03:27 ET | 3600 | 39.47 |
03:30 ET | 10115 | 39.36 |
03:32 ET | 1710 | 39.1551 |
03:34 ET | 6275 | 39.2 |
03:36 ET | 549 | 39.27 |
03:38 ET | 900 | 39.4 |
03:39 ET | 2600 | 39.48 |
03:41 ET | 7164 | 39.575 |
03:43 ET | 3733 | 39.705 |
03:45 ET | 3550 | 39.64 |
03:48 ET | 8747 | 39.3779 |
03:50 ET | 20766 | 39.48 |
03:52 ET | 14487 | 39.285 |
03:54 ET | 11465 | 39.49 |
03:56 ET | 18831 | 39.83 |
03:57 ET | 27909 | 39.81 |
03:59 ET | 193206 | 39.77 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cerevel Therapeutics Holdings Inc | 5.9B | -20.9x | --- |
Intra-Cellular Therapies Inc | 5.3B | -15.5x | --- |
Ascendis Pharma A/S | 4.8B | -11.3x | --- |
Karuna Therapeutics Inc | 6.8B | -33.6x | --- |
Cytokinetics Inc | 4.9B | -20.2x | --- |
Apellis Pharmaceuticals Inc | 7.1B | -9.5x | --- |
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. The Company is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, epilepsy and Parkinson’s disease. It is advancing diverse pipeline with numerous clinical trials underway or planned, including three ongoing Phase III trials and an open-label extension trial for tavapadon in Parkinson's, two planned Phase II trials and a planned open-label extension trial for emraclidine in schizophrenia and an ongoing Phase II proof-of-concept trial with an open-label extension trial for darigabat in focal epilepsy. Its pipeline candidates include Emraclidine, Darigabat, Darigabat and CVL-871.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 148.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.90 |
Book Value | $3.92 |
P/E Ratio | -20.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.